Day 20
$Pacific Biosciences of California(PACB.US$
My investment journey. Highlights of US stock trading day 20:
My investment journey. Highlights of US stock trading day 20:
My PENN shares took a dive today. But I’m taking it in stride. The Q3 earnings miss and Portnoy story do not really dim much of my optimism in the company. The main takeaway I’m interested in is the 11% revenue growth year on year. That is solid growth amid a less than 2 year foray into the sportsbook business via a partnership with Barstool.
Another highlight. I have always known that Illumina dominates the genome-sequencing industry. The explosive growth in genomics application for pharmaceutical and therapeutics development has fuel stellar returns for Illumina shareholders. The new frontier however, is the long-read methodology that PacBio improved and deploys. PacBio’s innovations will challange Illumina’s short-read sequencing. There is more than enough growth in the industry for these two different sequencing methodologies but I suspect that PacBio’s growth will outpace Illumina’s.
Another highlight. I have always known that Illumina dominates the genome-sequencing industry. The explosive growth in genomics application for pharmaceutical and therapeutics development has fuel stellar returns for Illumina shareholders. The new frontier however, is the long-read methodology that PacBio improved and deploys. PacBio’s innovations will challange Illumina’s short-read sequencing. There is more than enough growth in the industry for these two different sequencing methodologies but I suspect that PacBio’s growth will outpace Illumina’s.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Sage of SengkangOP : Correction: *11% revenue growth compared to 2019 Q3*